IP Library › Granted Patent US 10,016,381
Granted Patent B2
US 10,016,381 · App. 15/377,013 · Granted Jul 10, 2018

Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field

Inventors: Giancarlo Naccari (Monza, IT); Sergio Baroni (Villa d'adda, IT)
Assignee: Nogra Pharma Limited
A61K31/196C07C229/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,381
App. No.
15/377,013
Granted
Jul 10, 2018
Kind
B2
Abstract

The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

Claims (16)

1. A method of treating ulcerative rectocolitis in a mammal in need thereof, the method comprising administering to the mammal a compound represented by:

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The method of claim 1 , wherein the mammal is a human.

3. The method of claim 1 , wherein the compound is (R)-2-methoxy-3-(4′-aminophenyl)propionic acid.

4. The method of claim 1 , wherein the compound is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid.

5. The method of claim 1 , wherein the compound is in an enantiomerically pure R form.

6. The method of claim 1 , wherein the compound is in an enantiomerically pure S form.

7. A method of treating ulcerative rectocolitis in a mammal in need thereof, the method comprising administering to the mammal a pharmaceutical composition comprising:

a compound represented by:

or a pharmaceutically acceptable salt or a stereoisomer thereof; and

a pharmaceutically acceptable excipient.

8. The method of claim 7 , wherein the mammal is a human.

9. The method of claim 7 , wherein the compound is (R)-2-methoxy-3-(4′-aminophenyl)propionic acid.

10. The method of claim 7 , wherein the compound is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid.

11. The method of claim 7 , wherein the compound is in an enantiomerically pure R form.

12. The method of claim 7 , wherein the compound is in an enantiomerically pure S form.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2017
From: NACCARI, GIANCARLO; BARONI, SERGIO
To: GIULIANI INTERNATIONAL LIMITED
Reel/Frame 044054/0670 →
CHANGE OF NAME Recorded Nov 7, 2017
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 044392/0282 →
Priority Claims (1)
IT RM2005A0389 · Jul 22, 2005 · national
Continuity (5)
Continuation 14671579 · Mar 27, 2015
Division 14202386 · Mar 10, 2014
Continuation 13408439 · Feb 29, 2012
Division 11989090
Related Publication 20170312239A1 · Nov 2, 2017
Cited By (2)
US 12,291,494 US 12,509,416